Is a Combination of a GnRH Agonist and Recombinant Growth Hormone an Effective Treatment to Increase the Final Adult Height of Girls with Precocious or Early Puberty?

Table 1

Characteristics of included studies of girls with CPP.

Authors (year)	Comparison	Treatment	Duration of therapy	Subjects (n)	Before treatment					After treatment
					CA (years)	BA (years)	Height (cm)	HSDS	PAH (cm)	FAH (cm)	FAHSDS
Pasquino et al. 1999 [7]	GnRHa	Trip 100 μg/kg/21 days, i.m.	2–4 yr.	10 Italy	7.6 ± 0.2	10.4 ± 0.3	NA	−1.0 ± 0.3	155.5 ± 2.0	157.1 ± 2.5	−0.4 ± 0.3
	GnRHa + GH	Trip + GH 0.3 mg/kg/wk, sc.		10 Italy	10.0 ± 0.5	12.0 ± 0.2		−1.5 ± 0.2	152.7 ± 1.7	160.6 ± 1.3	0.2 ± 0.2
Proos et al. 2010 [24]	GnRHa	Buserelin 0.3 mg/4 wk, sc. implant	2–4 yr.	22 adopted	8.2 ± 0.8	9.7 ± 1.1	130.0 ± 7.4	0.3 ± 1.0	163.6 ± 6.5	155.8 ± 6.9	−1.6 ± 1.1
	GnRHa + GH	Buserelin + GH 0.1 U/kg/day, sc.		24 adopted	8.4 ± 0.8	10.2 ± 0.6	132.3 ± 5.6	0.5 ± 1.1	163.1 ± 5.6	158.9 ± 5.4	−1.1 ± 0.9
Mul et al. 2005 [22]	GnRHa	Trip 3.75 mg/28 days, i.m.	3 yr.	12 adopted	9.6 ± 0.9	10.7 ± 1.1	133.8 ± 8.7	−2.3 ± 0.6	149.8 ± 5.6	155.0 ± 5.6	−2.1 ± 0.9
	GnRHa + GH	Trip + GH 1.33 mg/m^2/day, sc.		14 adopted	9.6 ± 0.9	11.6 ± 0.8	135.1 ± 5.7	−1.8 ± 0.7	146.8 ± 4.8	155.0 ± 5.5	−2.1 ± 0.9
Liang et al. 2015 [25]	GnRHa	Trip 3.75 mg/28 days, sc.	8 yr.	17 China	8.1 ± 0.2	9.2 ± 0.3	132.8 ± 1.6	−0.5 ± 0.1	161.6 ± 0.9	159.8 ± 1.2	0.1 ± 0.3
	GnRHa + GH	Trip + GH 0.15–0.175 μg/kg/day, sc.		23 China	7.6 ± 0.3	8.4 ± 0.3	126.6 ± 1.8	−0.7 ± 0.2	160.0 ± 1.0	161.0 ± 1.0	−0.6 ± 0.2